 Levodopa
"Levodopa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
| Descriptor ID |
D007980
|
| MeSH Number(s) |
D02.092.311.200.480 D12.125.072.050.685.400.500 D12.125.072.050.875.130.500
|
| Concept/Terms |
Levodopa- Levodopa
- L-3,4-Dihydroxyphenylalanine
- L 3,4 Dihydroxyphenylalanine
- L-Dopa
- L Dopa
- 3-Hydroxy-L-tyrosine
- 3 Hydroxy L tyrosine
Dopaflex- Dopaflex
- Medphano Brand of Levodopa
Dopar- Dopar
- Roberts Brand of Levodopa
|
Below are MeSH descriptors whose meaning is more general than "Levodopa".
Below are MeSH descriptors whose meaning is more specific than "Levodopa".
This graph shows the total number of publications written about "Levodopa" by people in this website by year, and whether "Levodopa" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 1 | 1 | | 1981 | 3 | 1 | 4 | | 1982 | 2 | 3 | 5 | | 1983 | 2 | 2 | 4 | | 1984 | 1 | 1 | 2 | | 1985 | 0 | 1 | 1 | | 1986 | 1 | 1 | 2 | | 1987 | 3 | 1 | 4 | | 1988 | 1 | 1 | 2 | | 1989 | 2 | 0 | 2 | | 1990 | 0 | 2 | 2 | | 1991 | 1 | 0 | 1 | | 1992 | 0 | 1 | 1 | | 1993 | 2 | 1 | 3 | | 1995 | 1 | 0 | 1 | | 1996 | 3 | 0 | 3 | | 1997 | 2 | 1 | 3 | | 1998 | 2 | 3 | 5 | | 1999 | 3 | 2 | 5 | | 2000 | 2 | 0 | 2 | | 2001 | 2 | 2 | 4 | | 2002 | 1 | 0 | 1 | | 2003 | 3 | 2 | 5 | | 2004 | 1 | 1 | 2 | | 2005 | 0 | 3 | 3 | | 2006 | 1 | 5 | 6 | | 2007 | 1 | 0 | 1 | | 2008 | 2 | 1 | 3 | | 2009 | 1 | 5 | 6 | | 2010 | 1 | 0 | 1 | | 2013 | 2 | 1 | 3 | | 2016 | 1 | 1 | 2 | | 2017 | 2 | 0 | 2 | | 2019 | 1 | 0 | 1 | | 2020 | 2 | 2 | 4 | | 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Levodopa" by people in Profiles.
-
Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, de Bie RMA, Roze E, Miyasaki JM, Hauser RA, Espay AJ, Martello JP, Gurwell JA, Billinghurst L, Sullivan K, Fitts MS, Cothros N, Hall DA, Rafferty M, Hagerbrant L, Hastings T, O'Brien MD, Silsbee H, Gronseth G, Lang AE. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology. 2021 11 16; 97(20):942-957.
-
Hauser RA, LeWitt PA, Comella CL. On demand therapy for Parkinson's disease patients: Opportunities and choices. Postgrad Med. 2021 Sep; 133(7):721-727.
-
van Kessel SP, de Jong HR, Winkel SL, van Leeuwen SS, Nelemans SA, Permentier H, Keshavarzian A, El Aidy S. Gut bacterial deamination of residual levodopa medication for Parkinson's disease. BMC Biol. 2020 10 20; 18(1):137.
-
Dagan M, Herman T, Bernad-Elazari H, Gazit E, Maidan I, Giladi N, Mirelman A, Manor B, Hausdorff JM. Dopaminergic therapy and prefrontal activation during walking in individuals with Parkinson's disease: does the levodopa overdose hypothesis extend to gait? J Neurol. 2021 Feb; 268(2):658-668.
-
Lindestam Arlehamn CS, Dhanwani R, Pham J, Kuan R, Frazier A, Rezende Dutra J, Phillips E, Mallal S, Roederer M, Marder KS, Amara AW, Standaert DG, Goldman JG, Litvan I, Peters B, Sulzer D, Sette A. a-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease. Nat Commun. 2020 04 20; 11(1):1875.
-
Sellnow RC, Steece-Collier K, Altwal F, Sandoval IM, Kordower JH, Collier TJ, Sortwell CE, West AR, Manfredsson FP. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease. J Neurosci. 2020 04 29; 40(18):3675-3691.
-
van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, El Aidy S. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. Nat Commun. 2019 01 18; 10(1):310.
-
Kordower JH. What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias. Mov Disord. 2017 04; 32(4):483-484.
-
Voon V, Napier TC, Frank MJ, Sgambato-Faure V, Grace AA, Rodriguez-Oroz M, Obeso J, Bezard E, Fernagut PO. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. Lancet Neurol. 2017 03; 16(3):238-250.
-
Kordower JH, Vinuela A, Chu Y, Isacson O, Redmond DE. Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. J Comp Neurol. 2017 02 15; 525(3):498-512.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|